Manuscripts
Showing 1559 manuscripts.
Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants
Citation
Kathleen M. Powis, Mauricio Pinilla, Flynn McMorrow, Alice Stek, Kristina M. Brooks, David E. Shapiro, Kevin Knowles, Ahizechukwu C. Eke, Elizabeth Greene, Allison Agwu, Lourdes Topete, Renee Browning, Nahida Chakhtoura, Priyanka Arora, Xiaoying Huang, Brookie M. Best, Mark Mirochnick, Jeremiah D. Momper, IMPAACT 2026 Protocol Team. Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants. Journal of Acquired Immune Deficiency Syndromes. 2025. 98: 300-307. PMID: 39813286Year
2025
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
IMPAACT 2026
Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial
Citation
Tapiwa Mbengeranwa, Lauren Ziemba, Sean S. Brummel, Ben Johnston, Haseena Cassim, Gerhard Theron, Zukiswa Ngqawana, Deo Wabwire, Katie McCarthy, John Shepherd, Shahin Lockman, Lameck Chinula, Lynda Stranix-Chibanda, IMPAACT 2010/VESTED study team and investigators. Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial. Journal of AIDS. 2025. PMID: 40001275Year
2025
Journal
Journal of AIDS
Study
IMPAACT 2010
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Citation
Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M. Best, John H. Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M. Van Solingen-Ristea, Edmund V. Capparelli, Mark A. Marzinke, Elizabeth D. Lowenthal, Shawn Ward, Chelsea Krotje, Ryan Milligan, Allison L. Agwu, Jenny Huang, Amy Cheung, Cynthia McCoig, Dwight E. Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H. Gaur, IMPAACT 2017 Collaborators. Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2025. 12: e191-e200. PMID: 40049924Year
2025
Journal
Lancet HIV
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s.
Citation
Jennifer A. Hughes, Mauricio Pinilla, Kristina M. Brooks, Ahizechukwu C. Eke, Alice Stek, Brookie M. Best, Mark Mirochnick, Renee Browning, Lubbe Wiesner, Kathleen George, Kevin Knowles, Petra De Koker, Nahida Chakhtoura, Anneke C. Hesseling, Eric Decloedt, David E. Shapiro, Marije van Schalkwyk, IMPAACT P1026s Protocol Team. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s.. Clinical Pharmacology. 2025. 64: 619-630. PMID: 40155501Year
2025
Journal
Clinical Pharmacology
Study
P1026S
The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis
Citation
Sharon Sawe, Lufina Tsirizani, Richard Court, Kamunkhwala Gausi, Asanda Poswa, Tasnim Badat, Lubbe Wiesner, Marian Loveday, Gary Maartens, Francesca Conradie, Paolo Denti. The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. PMID: 40167446Year
2025
Journal
Antimicrobial Agents and Chemotherapy
Study
P1078
Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
Citation
Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Sarah Bradford, Tsungai Chipato, Tichoana Vhembo, Lynda Stranix-Chibanda, Deo Wabwire, Gaerolwe Masheto, Patrick Jean-Philippe, Timothy R Sterling, Adriana Weinberg, Amita Gupta. Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics. 2025. PMID: 40237651Year
2025
Study
P1078
Bone mineral density changes in breastfeeding women living with HIV on antiretroviral therapy in Eastern and Southern Africa
Citation
Flavia Matovu Kiweewa, Lynda Stranix-Chibanda, Nonhlanhla Yende-Zuma, Sufia Dadabhai, Maxensia Owor, Sherika Hanley, Mandisa Nyati, Lameck Chinula, John M Pettifor, Sean S Brummel, Jim Aizire, Taha E Taha, Todd T Brown, Mary Glenn Fowler, Maternal Bone Health Study team. Bone mineral density changes in breastfeeding women living with HIV on antiretroviral therapy in Eastern and Southern Africa. AIDS. 2025. PMID: 39918445Year
2025
Journal
AIDS
Study
P1084s
The Representative Studies Rubric: A Tool for Diversity in Clinical Trials
Citation
Brian Minalga, Rona Siskind, Russell Campbell, Tyler Adamson, Mary Allegra Cermak, Annet Davis, Eddie Givens, Molly Dyer, Katie McCarthy, Nicole A. MontaƱez, Rhonda White, RSR Working Group. The Representative Studies Rubric: A Tool for Diversity in Clinical Trials. American Journal of Bioethics. 2025. 1-15. PMID: 40293363Year
2025
Journal
American Journal of Bioethics
Model-informed once-daily dosing strategy for bedaquiline and delamanid in children, adolescents and adults with tuberculosis
Citation
Yu-Jou Lin, Louvina E. van der Laan, Mats O. Karlsson, Anthony J. Garcia-Prats, Anneke C. Hesseling, Elin M. Svensson. Model-informed once-daily dosing strategy for bedaquiline and delamanid in children, adolescents and adults with tuberculosis. Clinical Pharmacology & Therapeutics. 2025. 117: 1292-1302. PMID: 39731394Year
2025
Journal
Clinical Pharmacology & Therapeutics
Study
IMPAACT 2020
Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in HIV-1-Exposed Newborn Infant
Citation
Coleen K. Cunningham, Elizabeth J. McFarland, Petronella Muresan, Edmund V. Capparelli, Charlotte Perlowski, Benjamin Johnston, Frederic Bone, Lynette Purdue, Dwight E. Yin, Jack Moye, Hans M.L. Spiegel, Sai Majji, Gerhard B. Theron, Hilda A. Mujuru, Murli Purswani, Grace Alvarez, Jaime G. Deville, Carrie Chambers, Emily Brown, Paul A. Harding, Nicole H. Tobin, Kwang Low, Lucio Gama, IMPAACT P1112 Team. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in HIV-1-Exposed Newborn Infant. Journal of the Pediatric Infectious Diseases Society. 2025. 14: piaf002. PMID: 39821046Year
2025
Journal
Journal of the Pediatric Infectious Diseases Society
Study
P1112